Company intelligence / Profile preview

Domain

Illkirch-Graffenstaden, France

Ownership: Private
Employees: ~103
Development stage: Other

Overview

Domain Therapeutics is a clinical-stage biopharmaceutical company specializing in GPCR-targeted immunotherapies, with a focus on immuno-oncology. The company leverages its proprietary platform and biomarker strategy to develop first-in-class and best-in-class candidates, several of which are in clinical or preclinical development. Its lead programs are focused on overcoming resistance to current cancer immunotherapies. Domain has successfully completed a Phase 1 monotherapy dose escalation trial for its EP4 antagonist and is preparing for a Phase 2 trial in sarcoma, in collaboration with leading oncology experts[3][4][7].

Therapeutic areas: NeurologyRare DiseasesOncology
Modalities: Small moleculeAntibody
Industry: Biotech

Partnerships

PfizerMerck KGaABoehringer IngelheimOno PharmaceuticalBristol Myers Squibb

Beyond the preview

Go deeper on Domain.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Domain.

Explore the full profile